UniQure Gene Therapy’s Clinical Trial Results Keep It on Path to Become First Huntington’s Treatment
UniQure plans a first quarter 2026 FDA submission for AMT-130 as a treatment for Huntington’s disease. This gene therapy delivers microRNA designed to silence the mutated gene that produces a protein driving this disorder, which so far has no FDA-approved therapies.
Healthcare’s Security Awakening Testing Patience of Medical Device Buyers
Customers are no longer willing to accept vague assurances about security. Instead, they expect evidence of secure design, documented vulnerability management processes, and transparency about software components.
Rush To Regulation: What New NHS Compliance Requirements For Ambient Voice Technology Mean For US Providers
The proliferation and rapid adoption of AVT in clinical settings has not gone unnoticed, and NHS England has made it clear that the use of these tools must now meet stringent compliance standards.
Capital Rx Rebrands as Judi Health After Securing $400M Investment
Capital Rx has secured a $400 million investment, including a $252 million Series F round led by Wellington Management and General Catalyst. It is also rebranding as Judi Health to reflect its expansion beyond pharmacy benefits.
How Sutter Health Uses AI Agents to Handle Patients’ Scheduling, Refills & Billing Questions
Sutter Health is rolling out Hyro’s AI agents, which give patients 24/7 support for things like scheduling, prescription refills and billing questions. These agents aim to make routine healthcare interactions faster and easier, while also freeing up staff to handle more complex cases and providing data insights to improve the overall patient experience.